Navigation Links
Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Date:10/17/2010

and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com. Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

(650) 631-4954Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650Nektar Media Inquiries: Karen Bergman/BCC Partners

(650) 575-1509 Michelle Corral/BCC Partners

(415) 794-8662This press release contains forward-looking statements that reflect Nektar's current views as to the potential of NKTR-181 to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies, the timing of the start of Phase 1 clinical studies for NKTR-181, the potential of Nektar's polymer conjugate technology platform, and the potential for certain of Nektar's other drug candidates.  These forward-looking statements involve substantial risks and uncertainties including but not limited to one or more of the following: (i) the preclinical data for NKTR-181 described in this press release and presented at the Pain 2010 Conference may not be predictive of future success in clinical trials; (ii) the commencement of a Phase 1 clinical study for NKTR-181 could be delayed due to regulatory factors, the need to successfully complete certain toxicology studies, drug manufacturing challenges, or other important factors that can impact clinical development efforts; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates such as NKTR-181 is therefore very uncertain and unpredict
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 In today,s increasingly global marketplace ... to reflect the needs of a global marketplace ... the needs of key stakeholders while recognizing regional ... According to recent research by benchmarking firm, Best ... companies averaged more than $100,000 in annual spending ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... FORT WORTH, Texas , December 18, 2014 ... is a networked software application/module that is used ... and related images. RIS comprises a patient tracking ... tracking system. The integration of RIS with HIS ... is used for patient registration and patient scheduling, ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3
... reduce the use of mechanical ventilation with premature infants in ... affect those children,s outcomes while reducing the cost of care, ... The team, led by Bernadette Levesque, MD, ... and the Neonatal Intensive Care Unit (NICU) at St. Elizabeth,s ...
... SPRING, Md., June 10, 2011 The U.S. Food ... Merck,s redesigned drug container labels that include a new ... on product and strength differentiation. (Logo: ... the revision of 34 container labels for 16 solid ...
Cached Medicine Technology:Guidelines for Ventilator Use Help Premature Infants Breathe Easier 2Guidelines for Ventilator Use Help Premature Infants Breathe Easier 3FDA Approves Redesigned Labels for Some Merck Drugs 2
(Date:12/19/2014)... December 20, 2014 Today, Balfleet.com ... special-occasion outfits, announces its formal dress promotion. All the ... up to 60% off. , Balfleet.com is well-known for ... bridesmaid dresses, prom dresses, cocktail dresses and more. Its ... 30-day money-back guarantee, and they can create an elegant ...
(Date:12/19/2014)... Energy Textiles is excited to ... Celliant, the world’s leading responsive textile, can now ... There are a number of benefits to wearing ... and balanced body temperature; which can lead to ... enhanced athletic performance; and overall wellness. In addition, ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Eufaula, Oklahoma, ... to Lake Eufaula, the state’s largest lake with more ... town is home to a little more than 3,000 ... P.M. on Saturday, the 6th of December. , Featuring ... way through downtown Eufaula on Main Street. Narconon ...
(Date:12/19/2014)... The print component of Vision and ... of the Toronto Star, with a circulation of approximately ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... publication features an exclusive interview with Mark DeMontis ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Potentially illness-causing ... herbs bought at farmers markets, according to a new ... almost 50 vendors from 13 farmers markets in Los ... Seattle area. Out of almost 150 samples tested, 24 ... positive for salmonella, according to the researchers. Both ...
Breaking Medicine News(10 mins):Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... ... best hospitals in the United States by U.S. News & World Report. , ... New York, NY (Vocus) July 16, 2009 -- The Mount Sinai Medical ... States by U.S. News & World Report. , , ,In the 2009-10 America,s Best Hospital issue, Mount ...
... , BOCA RATON, Fla., July 16 JAG ... further update of the status of its acquisition of CardioGenics ... closing date for the acquisition, currently scheduled for a date ... a date on or before July 24, 2009 to allow ...
... ... their practices and prepare for the future just launched on Monday. , ... (Vocus) July 16, 2009 -- The ... 25 years of combined experience in dental practice sales and appraisals, is the first membership-based, ...
... , , WASHINGTON, July 16 ... committees crafting the House version of a health care reform bill ... those revenues to a special fund to finance prevention and wellness ... taxes are an important tool in reducing the public health toll ...
... to higher risk of heart attack, stroke, agency says, ... Food and Drug Administration has begun a safety review ... an increased risk of heart attack, abnormal heart rhythm, ... Early results from the Evaluating the Clinical Effectiveness and ...
... , , , BEDFORD, Ohio, ... Inc., announced FDA approval to begin shipping Ceftriaxone for Injection USP. ... by Roche. Ceftriaxone is a semisynthetic, broad-spectrum antibiotic used to ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO ...
Cached Medicine News:Health News:The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals 2Health News:The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals 3Health News:JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc. 2Health News:National Practice Transition Network Launches as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company 2Health News:Raise Federal Alcohol Tax to Finance Prevention Trust Fund, Partnership Urges House Chairmen 2Health News:FDA Investigating Safety of Asthma Drug Xolair 2Health News:Bedford Laboratories(TM) to Begin Shipping Ceftriaxone for Injection USP 2
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
STABIBAG Hydrophilic Acrylic Lens....
BIGBAG Hydrophilic Acrylic Lens for high myopia....
One piece multifocal acrylic intraocular lens....
Medicine Products: